ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
Portfolio
17/10/2023 - 10:56 | Portfolio
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its lead compound IOS-1002 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in an ongoing Phase 1a/b clinical trial for the treatment of patients with advanced solid tumors.
Do you want to stay updated about the press releases?